

Sample Size Considerations for Comparing Dynamic Treatment Regimens in a SMART with a Longitudinal Outcome

Nicholas J. Seewald

Department of Statistics
University of Michigan

Joint with K.M. Kidwell, J.R. McKay, I. Nahum-Shani, T. Wu, D. Almirall

JSM 2019

30 July 2019

Motivating Example: The ENGAGE Study

In treating alcohol- and cocaine-dependent patients, there is a question as to how best to re-engage individuals who do not engage in treatment.

-
- McKay, J. R., et al. (2015). *J. Consult. Clin. Psychol.*

Motivating Example: The ENGAGE Study

In treating alcohol- and cocaine-dependent patients, there is a question as to how best to re-engage individuals who do not engage in treatment.

For these individuals, should we attempt to re-engage them in their original treatment, or offer them a choice of treatment modality?

• McKay, J. R., et al. (2015). *J. Consult. Clin. Psychol.*

Motivating Example: The ENGAGE Study

In treating alcohol- and cocaine-dependent patients, there is a question as to how best to re-engage individuals who do not engage in treatment.

For these individuals, should we attempt to re-engage them in their original treatment, or offer them a choice of treatment modality?

What do we do if that doesn't work?

• McKay, J. R., et al. (2015). *J. Consult. Clin. Psychol.*

Motivating Example: The ENGAGE Study

In treating alcohol- and cocaine-dependent patients, there is a question as to how best to re-engage individuals who do not engage in treatment.


For these individuals, should we attempt to re-engage them in their original treatment, or offer them a choice of treatment modality?

What do we do if that doesn't work?

This is a question about a *sequence* of treatments.

• McKay, J. R., et al. (2015). *J. Consult. Clin. Psychol.*

Dynamic treatment regimens (DTRs) operationalize clinical decision-making by recommending particular treatments to certain subsets of patients at specific times.



- **MI-IOP:** 2 motivational interviews to re-engage patient in intensive outpatient program
- **MI-PC:** 2 motivational interviews to engage patient in treatment of their choice.

• Chakraborty, B., and E. E. M. Moodie (2013). *Statistical Methods for Dynamic Treatment Regimes*.

Sequential, Multiple-Assignment Randomized Trials


A **SMART** is one type of randomized trial design that can be used to answer questions at multiple stages of the development of a high-quality DTR.

Sequential, Multiple-Assignment Randomized Trials

A **SMART** is one type of randomized trial design that can be used to answer questions at multiple stages of the development of a high-quality DTR.


The key feature of a SMART is that some (or all) participants are randomized *more than once*.

Motivating Example: The ENGAGE Study




- McKay, J. R., et al. (2015). *J. Consult. Clin. Psychol.*

Four Embedded DTRs in ENGAGE




Four Embedded DTRs in ENGAGE

$d = 2$




Four Embedded DTRs in ENGAGE



Four Embedded DTRs in ENGAGE

$d = 4$




A common primary aim in a SMART

is the comparison of two embedded DTRs using a continuous outcome collected at the end of the study.


Primary Aim

$d = 1$

$d = 3$



An Example Model for a Continuous Longitudinal Outcome in ENGAGE (Lu et al. 2016)



$$\begin{aligned}
 E \left[Y_t^{(d)} \mid \mathbf{X} \right] &:= \mu^{(d)}(\mathbf{X}_i; \eta, \gamma) \\
 &= \eta^\top \mathbf{X}_i + \gamma_0 \\
 &\quad + \mathbb{1}\{t \leq t^*\} \{ \gamma_1 t + \gamma_2 \mathbf{a}_1 t \} \\
 &\quad + \mathbb{1}\{t > t^*\} \{ t^* \gamma_1 + t^* \gamma_2 \mathbf{a}_1 \\
 &\quad \quad + \gamma_3 (t - t^*) + \gamma_4 (t - t^*) \mathbf{a}_1 \\
 &\quad \quad + \gamma_5 (t - t^*) \mathbf{a}_{2NR} \\
 &\quad \quad + \gamma_6 (t - t^*) \mathbf{a}_1 \mathbf{a}_{2NR} \}
 \end{aligned}$$

	d = 1	d = 2	d = 3	d = 4
a₁	1	1	-1	-1
a_{2R}	0	0	0	0
a_{2NR}	1	-1	1	-1

“GEE-Type” Estimating Equations for Model Parameters

$$0 = \sum_{i=1}^N \sum_d \left[\frac{I^{(d)}(A_{1,i}, R_i, A_{2,i})}{\underbrace{P(A_{1,i} = a_1)P(A_{2,i} = a_2 | A_{1,i} = a_1, R_i)}_{W^{(d)}(A_{1,i}, R_i, A_{2,i})}} \cdot \mathbf{D}^{(d)}(\mathbf{X}_i)^\top \cdot \mathbf{V}^{(d)}(\boldsymbol{\tau})^{-1} \cdot \left(\mathbf{Y}_i - \boldsymbol{\mu}^{(d)}(\mathbf{X}_i; \boldsymbol{\eta}, \boldsymbol{\gamma}) \right) \right],$$

where

- d specifies an embedded DTR,
- $W^{(d)}(A_{1,i}, R_i, A_{2,i}) = \mathbb{1}\{A_{1,i} = a_1\} \left(2R_i + 4(1 - R_i) \mathbb{1}\{A_{2,i} = a_2\} \right)$
- $\mathbf{D}^{(d)}(\mathbf{X}_i) = \frac{\partial}{\partial(\boldsymbol{\eta}^\top, \boldsymbol{\gamma}^\top)^\top} \boldsymbol{\mu}^{(d)}(\mathbf{X}_i; \boldsymbol{\eta}, \boldsymbol{\gamma})$
- $\mathbf{V}^{(d)}(\boldsymbol{\tau})$ is a working model for $\mathbf{Var} \left(\mathbf{Y}^{(d)} - \boldsymbol{\mu}^{(d)}(\mathbf{X}_i; \boldsymbol{\eta}, \boldsymbol{\gamma}) \mid \mathbf{X}_i \right)$

• Lu, X., et al. (2016). *Stat. Med.*

Goal:

For this analysis, develop a sample size formula for SMARTs with a continuous longitudinal outcome in which the primary aim is to compare, at end-of-study, two embedded DTRs which recommend different first-stage treatments.

Context:

- Three timepoints
- Randomization probability 0.5
- Exchangeable correlation structure

Sample Size for an End-of-Study Comparison

$$N \geq \frac{4 \left(z_{1-\alpha/2} + z_{1-\beta} \right)^2}{\delta^2} \cdot (1 - \rho^2) \cdot (2 - r)$$

where

- $\delta = E[Y_2^{(d)} - Y_2^{(d')}] / \sqrt{(\text{Var}(Y_2^{(d)}) + \text{Var}(Y_2^{(d')}))} / 2$ is the targeted standardized effect size
- α is the desired type-I error
- $1 - \beta$ is the desired power
- $\rho = \text{cor}(Y_t, Y_{t'})$ for $t \neq t'$
- $r = P(R_i = 1)$

Sample Size for an End-of-Study Comparison

$$N \geq \underbrace{\frac{4 \left(z_{1-\alpha/2} + z_{1-\beta} \right)^2}{\delta^2}}_{\text{Standard sample size for a 2-arm trial}} \cdot (1 - \rho^2) \cdot (2 - r)$$

where

- $\delta = E[Y_2^{(d)} - Y_2^{(d')}] / \sqrt{(\text{Var}(Y_2^{(d)}) + \text{Var}(Y_2^{(d')}))} / 2$ is the targeted standardized effect size
- α is the desired type-I error
- $1 - \beta$ is the desired power
- $\rho = \text{cor}(Y_t, Y_{t'})$ for $t \neq t'$
- $r = P(R_i = 1)$

Sample Size for an End-of-Study Comparison

$$N \geq \frac{4 \left(z_{1-\alpha/2} + z_{1-\beta} \right)^2}{\delta^2} \cdot \underbrace{(1 - \rho^2)}_{\text{Deflation for repeated measures}} \cdot (2 - r)$$

where

- $\delta = E[Y_2^{(d)} - Y_2^{(d')}] / \sqrt{(\text{Var}(Y_2^{(d)}) + \text{Var}(Y_2^{(d')}))} / 2$ is the targeted standardized effect size
- α is the desired type-I error
- $1 - \beta$ is the desired power
- $\rho = \text{cor}(Y_t, Y_{t'})$ for $t \neq t'$
- $r = P(R_i = 1)$

Sample Size for an End-of-Study Comparison

$$N \geq \frac{4 \left(z_{1-\alpha/2} + z_{1-\beta} \right)^2}{\delta^2} \cdot (1 - \rho^2) \cdot \underbrace{(2 - r)}$$

Inflation for SMART design

where

- $\delta = E[Y_2^{(d)} - Y_2^{(d')}] / \sqrt{(\text{Var}(Y_2^{(d)}) + \text{Var}(Y_2^{(d')}))} / 2$ is the targeted standardized effect size
- α is the desired type-I error
- $1 - \beta$ is the desired power
- $\rho = \text{cor}(Y_t, Y_{t'})$ for $t \neq t'$
- $r = P(R_i = 1)$

Sample Size for an End-of-Study Comparison

Table 1: Example sample sizes for comparison of two embedded DTRs. $r = 0.4$, $\alpha = 0.05$ (two-sided), and $1 - \beta = 0.8$.

Std. Effect Size	Within-Person Correlation		
	$\rho = 0$	$\rho = 0.3$	$\rho = 0.6$
$\delta = 0.3$	559	508	358
$\delta = 0.5$	201	183	129

Working Assumptions for Sample Size

1. *Response is uncorrelated with products of first-stage residuals. For any $t_i \leq t_j \leq t^*$,*

$$\text{Cov} \left(R^{(a_1)}, \left(Y_{t_i}^{(d)} - \mu_{t_i}^{(d)} \right) \left(Y_{t_j}^{(d)} - \mu_{t_j}^{(d)} \right) \right) = 0$$

• Oetting, A. I., et al. (2011).

Working Assumptions for Sample Size

1. *Response is uncorrelated with products of first-stage residuals.* For any $t_i \leq t_j \leq t^*$,

$$\text{Cov} \left(R^{(a_1)}, \left(Y_{t_i}^{(d)} - \mu_{t_i}^{(d)} \right) \left(Y_{t_j}^{(d)} - \mu_{t_j}^{(d)} \right) \right) = 0$$

2. *Constrained conditional covariances.*

$$2.1 \quad E \left[\left(Y_2^{(d)} - \mu_2^{(d)} \right)^2 \mid R^{(a_1)} = 0 \right] \leq \text{Var} \left(Y_2^{(d)} \right)$$

$$2.2 \quad \text{Cov}(Y_t^{(d)}, Y_2^{(d)} \mid R = 1) \leq \text{Cov}(Y_t^{(d)}, Y_2^{(d)} \mid R = 0) \text{ for all } d \text{ and } t = 0, 1.$$

• Oetting, A. I., et al. (2011).

3. *Exchangeable correlation structure.*

$$\text{Var}(\mathbf{Y}^{(d)}) = \sigma^2 \begin{bmatrix} 1 & \rho & \rho \\ \rho & 1 & \rho \\ \rho & \rho & 1 \end{bmatrix}$$

for all d .

Simulation Results

Target: $1 - \beta = 0.8$, $\alpha = 0.05$ (two-sided)

δ	$P(R = 1)$	ρ	N	Empirical power			
				All satisfied	1 violated	2.1 violated	2.2 violated
0.3	0.4	0	559	0.801	0.778*	0.803	-
		0.3	508	0.804	0.800	0.797	0.798
		0.6	358	0.817	0.807	0.759*	0.788
		0.8	201	0.836	0.809	-	0.792
	0.6	0	489	0.804	0.736*	0.810	-
		0.3	445	0.797	0.758*	0.795	0.780*
		0.6	313	0.824	0.793	0.752*	0.770*
		0.8	176	0.845	0.754*	-	0.776*

* Result is significantly less than 0.8 at the 0.05 significance level.

Funding

This work was supported by the following awards from the National Institutes of Health: R01DA039901, P50DA039838, R01HD073975, R03MH097954, P01AA016821, RC1AA019092, U54EB020404. The content of this presentation is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.



<https://nickseewald.com>


Extra Slides

Working Assumptions for Sample Size

1. Response is uncorrelated with products of first-stage residuals. For any $t_i \leq t_j \leq t^*$,

$$\text{Cov} \left(R^{(a_1)}, \left(Y_{t_i}^{(d)} - \mu_{t_i}^{(d)} \right) \left(Y_{t_j}^{(d)} - \mu_{t_j}^{(d)} \right) \right) = 0$$

Intuition: If this is not true, the relationship between, say $Y_1^{(d)}$ and R might look like this:



Two Definitions of Response

$$R^{(a_1)} = \mathbb{1} \left\{ \left(Y_1^{(d)} \right)^2 > 4.7 \right\}$$



$$R^{(a_1)} = \mathbb{1} \left\{ Y_1^{(d)} > 0.7 \right\}$$

